Alkem Laboratories Ltd

Alkem Laboratories Dividend

Alkem Laboratories recommended a final dividend of Rs. 10 per equity share for FY 2025-26. The board also approved re-appointing Mrs. Madhurima Singh as Executive Director.

Alkem Laboratories Q4 FY26 Results: Net Profit ₹236.5 Cr, Down 22.7% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,603 Cr (+14.6% YoY) and net profit of ₹236.5 Cr (-22.7% YoY) for Q4 FY26.

Key figure

Net profit ₹236.5 Cr · -22.7% YoY

Alkem Laboratories Financial Results

Alkem Laboratories reported a consolidated annual profit of ₹2,351.16 Crore for FY26. The board recommended a final dividend of ₹10 per equity share.

Value

₹2,351 Cr

Alkem Laboratories Management Change

Alkem Laboratories re-appointed Mrs. Madhurima Singh as Executive Director for a five-year term starting December 2026. This move ensures leadership continuity through 2031.

Execution

5 years

Alkem Laboratories Q4 FY26 Results: Net Profit ₹251.1 Cr, Down 22.1% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,603 Cr (+14.6% YoY) and net profit of ₹251.1 Cr (-22.1% YoY) for Q4 FY26.

Key figure

Net profit ₹251.1 Cr · -22.1% YoY

Alkem Laboratories Financial Results

Alkem Laboratories reported audited FY26 financial results and recommended a final dividend of Rs. 10 per share. The board also re-appointed Mrs. Madhurima Singh as Executive Director.

Alkem Laboratories Board Meeting Date

Alkem Laboratories scheduled a board meeting for May 28, 2026. Directors will consider audited financial results and recommend a final dividend for shareholders.

Alkem Laboratories Management Change

Alkem Laboratories appointed Mr. Chanakya Misra to a senior management position effective May 18, 2026. He brings over 25 years of pharmaceutical and healthcare experience.

Execution

Duration of employment contract

Alkem Laboratories Business Update

Alkem Laboratories' Taloja CRO facility successfully cleared an unannounced US FDA inspection. No Form 483 observations were issued, confirming compliance with international regulatory standards.

Alkem Laboratories Legal & Regulatory

Alkem Laboratories Limited received a favorable order dropping a GST demand of ₹69.66 Crore, including interest and penalties. The order from Mumbai GST authorities relates to alleged incorrect ITC/refund claims. The company stated there is no material impact on its financial or operational activities.

Value

₹69.66 Cr

Alkem Laboratories Business Update

Alkem Laboratories Limited's manufacturing facility in Amaliya, Daman, underwent a US FDA inspection from April 20 to May 1, 2026. The company received Form 483 with seven observations and intends to address them within the stipulated timeframe. This is a routine regulatory update regarding facility compliance.

Alkem Laboratories Legal & Regulatory

Alkem Laboratories received an income tax assessment order for AY 2023-24 with a disputed tax amount of ₹333.38 Crore. The dispute relates to 80IE deduction disallowance and transfer pricing adjustments. The company states no cash outflow is expected due to MAT credit utilization and plans to appeal the order.

Value

₹333.4 Cr

Alkem Laboratories Management Change

Dr. Vikas Gupta has resigned as Chief Executive Officer of Alkem Laboratories Ltd to pursue new professional opportunities. He will continue in his role until June 30, 2026, to ensure a smooth transition of responsibilities.

Alkem Laboratories Merger & Restructuring

Alkem Laboratories Limited incorporated a new wholly-owned subsidiary, Alkem Pharma Trading FZCO, in the UAE on March 27, 2026. The new entity will focus on exporting pharmaceutical products to African, South East Asian, and non-UAE markets. This strategic move aims to expand the company's international footprint and export capabilities.

Alkem Laboratories Merger & Restructuring Worth ₹9.18 Cr

Alkem Laboratories Limited incorporated a wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE, on March 27, 2026. The ₹9.18 Crore investment aims to facilitate pharmaceutical exports to African, South East Asian, and non-UAE markets. This strategic move strengthens Alkem's international presence and export capabilities.

Value

₹9.18 Cr

Alkem Laboratories Results Correction

Alkem Laboratories Limited submitted revised XBRL financial results for the quarter ended March 31, 2025, following a clarification request from the National Stock Exchange. The revision addresses discrepancies regarding the 'audited' status of the results. This is a administrative correction to ensure regulatory compliance.

Alkem Laboratories Product Launch

Alkem Laboratories Limited has launched 'A to Z Daily', a comprehensive multivitamin supplement for adults. Formulated with 26 vitamins, minerals, and botanicals like Ashwagandha, the FSSAI-approved product targets stress management and immunity. This launch strengthens Alkem's growing portfolio in the wellness and nutritional supplement segment.

Alkem Laboratories Other Announcement

Alkem Laboratories' promoter, Basudeo N. Singh, has declared that the promoter group made no direct or indirect encumbrances on their shareholding during FY 2025-26. This is a routine annual compliance disclosure under SEBI Takeover Regulations.

Alkem Laboratories Q3 FY26 Results: Net Profit ₹653 Cr, Up 1.9% YoY

Alkem Laboratories Ltd reported net profit of ₹653 Cr (+1.9% YoY) for Q3 FY26.

Key figure

Net profit ₹653 Cr · +1.9% YoY